Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction

Natalia Sharova

University of Massachusetts Medical School

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Repository Citation
Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey ME, Stevenson M. (2008). Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. Open Access Publications by UMass Chan Authors. https://doi.org/10.1371/journal.ppat.1000057. Retrieved from https://escholarship.umassmed.edu/oapubs/2029

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMass Chan Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Primate Lentiviral Vpx Commandeers DDB1 to Counteract a Macrophage Restriction

Natalia Sharova, Yuanfei Wu, Xiaonan Zhu, Ruzena Stranska, Rajnish Kaushik, Mark Sharkey, Mario Stevenson

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

Abstract

Primate lentiviruses encode four “accessory proteins” including Vif, Vpu, Nef, and Vpr/Vpx. Vif and Vpu counteract the antiviral effects of cellular restrictions to early and late steps in the viral replication cycle. We present evidence that the Vpx proteins of HIV-2/SIVSM promote virus infection by antagonizing an antiviral restriction in macrophages. Fusion of macrophages in which Vpx was essential for virus infection, with COS cells in which Vpx was dispensable for virus infection, generated heterokaryons that supported infection by wild-type SIV but not Vpx-deleted SIV. The restriction potentially antagonized infection of macrophages by HIV-1, and expression of Vpx in macrophages in trans overcame the restriction to HIV-1 and SIV infection. Vpx was ubiquitylated and both ubiquitylation and the proteasome regulated the activity of Vpx. The ability of Vpx to counteract the restriction to HIV-1 and SIV infection was dependent upon the HIV-1 Vpr interacting protein, damaged DNA binding protein 1 (DDB1), and DDB1 partially substituted for Vpx when fused to Vpr. Our results indicate that macrophage harbor a potent antiviral restriction and that primate lentiviruses have evolved Vpx to counteract this restriction.

Introduction

The genomes of primate and non-primate lentiviruses encode “accessory” proteins from short open reading frames which are absent from the genomes of simple retroviruses [1]. The function of two of the accessory proteins, the Vif and Vpu proteins, have been defined: Vif antagonizes the antiviral activity of cellular Apobec 3 cytidine deaminases [2] and Vpu antagonizes the activity of tetherin to promote release of virions from the cell surface [3]. In all HIV and SIV lineages, the central viral region (overlapping Vif and Tat open reading frames) encodes at least one gene which is usually termed viral protein R (Vpr). Members of the HIV-2/SIVSM/SIVMAC lineage contain an additional gene in this region termed viral protein X (Vpx) which was originally derived from the African green monkey vpr gene by an ancestral recombination event [4]. Both Vpr and Vpx proteins are packaged into virions through association with the Gag polyprotein [5–7] and this points to an early role for these proteins in the virus life cycle (i.e., at a point proceeding de novo production of viral proteins). Most of the information regarding the roles of Vpr and Vpx proteins in primate lentivirus replication has been derived from studies with HIV-1 Vpr. The Vpr protein of HIV-1 has been shown to promote the accumulation of cells in the G2 stage of the cell cycle [8–11] and to associate with the DNA repair enzyme Uracil DNA glycosylase[12]. In addition, Vpr has been shown to promote the infection of terminally differentiated macrophages and dendritic cells [13–17]. These HIV-1 Vpr-ascribed activities segregate between the Vpx and Vpr proteins of HIV-2/SIVSM: Vpr of HIV-2/SIVSM induces cell cycle arrest and associates with UDG but is dispensable for macrophage infection while Vpx neither induces cell cycle arrest nor associates with UDG [4,18]. However, Vpx is essential for infection of simian macromolecules by SIV in vitro and following infection of simian macrophages by Vpx minus SIVSM, late cDNA product are reduced while 2-LTR cDNAs, which are formed only after completion of reverse transcription, are absent [4,18]. Whether any of these activities relate to the functional role of Vpr/Vpx proteins in primate lentivirus replication, is unclear. In order to understand the functions of the Vpr/Vpx proteins in macrophage infection, we have focused on Vpx because of its profound impact on macrophage infection. In addition, its effect can be studied independently of other Vpr/Vpx-assigned activities including UDG association and cell cycle arrest.

Results

Vpx is required for infection of heterokaryons between permissive and non-permissive cells

We previously demonstrated that Vpx of HIV-2/SIVSM was essential for early events in macrophage infection yet dispensable for infection of CD4 lymphocytes [4]. We studied Vpx function in the context of SIVSM PBj which represents a primary isolate [19]. To increase particle infectivity and facilitate analysis of early events in the viral life cycle, viruses were pseudotyped with VSV-G envelope proteins. Although VSV pseudotyping has been shown to alleviate the defects exhibited by other accessory gene mutants...
Defense against infection by the primate lentiviruses HIV/SIV is mediated primarily by antibodies that can neutralize the virus and by cytotoxic cells that can recognize and kill other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3-fold defect in late cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses. Although 2-LTR cDNA was not detected in other virus-infected cells. However, in the past several years, research has revealed the existence of an additional layer of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibi...
Vpx was expressed in 293 T cells and cell lysates were directly Western blotted and probed with an HA antibody. This revealed the presence of higher molecular weight ubiquitylated forms of Vpx (Figure 3A, right panel). The extent of Vpx ubiquitylation was reduced to various extents in Vpx mutants containing single or multiple lysine to arginine substitutions (Figure 3A). Despite mutagenesis of all four lysines in Vpx, polyubiquitylated forms of the protein were still evident (compare GFP signal with VpxM4 signal). This suggested an involvement of both lysine and nonlysine residues in Vpx ubiquitylation [24,25]. The ability of the Vpx lysine mutants to support SIV infection of macrophages was next examined. The various mutants were packaged within SIVΔVpx virions and single cycle infection of macrophages was evaluated from synthesis of late viral cDNAs and 2-LTR cDNAs (Figure 3B). The infectivity of the Vpx lysine mutants was impaired to various degrees (Figure 3B). The Vpx mutant lacking all four lysine (VpxM4) exhibited the lowest infectivity for macrophage. However, a mutant lacking the two N-terminal lysines (VpxNM2) appeared to be efficiently ubiquitylated yet this mutant also exhibited a significant infectivity defect (Figure 3B). However, due to technical obstacles in transfection of primary macrophages, we were unable to evaluate the extent of Vpx ubiquitylation of the various lysine mutants in primary macrophages and for this reason, we were unable to directly assess whether the extent of Vpx ubiquitylation was proportional to Vpx biological activity. For subsequent experiments, we focused on the use of Vpx mutant (VpxM4) containing substitutions at all four lysine residues. This mutant was efficiently packaged within virus particles at levels indistinguishable from wild type Vpx (Figure 3C). The packaging of the Vpx lysine mutant in viral particles suggests, at the very least, that this mutant is competent for binding to the p6 domain of the viral Gag polyprotein through which packaging of Vpr and Vpx proteins is mediated [5,6].
Vpx activity requires a functional proteasome

We next examined whether the ability of Vpx to regulate SIV infection of macrophages required proteasome function. Macrophages were treated with three different proteasome inhibitors and then infected with wild type SIV and 2-LTR cDNA was quantitated 24 and 48 hours after infection. Lactacystin had a...
The macrophage restriction is active against HIV-1

We next evaluated whether the antiviral restriction which antagonized HIV-2/SIV<sub>SM</sub> infection of macrophages was active against HIV-1. We first examined whether the Vpx protein, when packaged in trans within HIV-1 virions, enhanced virus infectivity for primary macrophages. While Vpx had no significant effect on the infectivity of wild type HIV-1, the infectivity of HIV-1ΔVpr for macrophages was profoundly enhanced by Vpx but not by HIV-1 Vpr (Figure 5A, lower panel). The infectivity enhancement was also apparent in macrophages infected with an HIV-1 variant expressing green fluorescent protein (GFP) (Figure 5B). Thus, while HIV-1 was infectious for macrophages, its ability to infect these cells was markedly enhanced in the presence of Vpx. Vpx had no effect on the infectivity of wild type or ΔVpr HIV-1 for COS cells (Figure 5A, upper panel). A possible explanation for the ability of Vpx to complement HIV-1 ΔVpr but not wild-type HIV-1 is that Vpx and HIV-1 Vpr proteins compete for packaging within HIV-1 virions. An alternative possibility was that these proteins do not compete for packaging into virions but compete for interaction with the restriction after infection has occurred. Western blotting analysis revealed that both wild type and lysine mutant (Vpx<sub>M4</sub>) Vpx proteins were packaged into wild type and Vpr deleted HIV-1 virions (Figure 5C). This suggested that HIV-1 Vpr competed with Vpx in the target cell following infection and this competition precluded the ability of Vpx to activate the restriction. A prediction of this is that delivery of Vpx to this target cell prior to HIV-1 infection should be sufficient to inactivate the restriction and subsequently enhance macrophage infection by both wild type and Vpr deleted HIV-1. To evaluate this, we bypassed the requirement for Vpx packaging by directly introducing Vpx into the target cell by SIV<sub>WT</sub> infection. The susceptibility of those cells to infection by wild type or Vpr-deleted HIV-1 variants was then examined. In this case, the infectivity of both wild type and vpr deleted HIV-1 variants for macrophages was enhanced when Vpx was first introduced into the cell by SIV<sub>WT</sub> infection (Figure 5D). In contrast, prior infection with a SIVΔVpx variant did not enhance subsequent HIV-1 infection of macrophages (Figure 5D). Therefore, in the absence of competition by packaged Vpr, Vpx greatly enhanced HIV-1 infectivity for macrophages. We next evaluated whether the ability of Vpx to enhance HIV-1 infectivity depended upon its ubiquitylation. As was the case for SIV, a Vpx mutant lacking ubiquitylation sites (Vpx<sub>Δub</sub>) did not enhance HIV-1 infectivity when packaged within HIV-1ΔVpr virions (Figure 6A). This was also apparent in infections using indicator viruses (Figure 6B). In this case, the ability of Vpx to enhance the infectivity of a Vpr deleted HIV-1 variant expressing GFP was compromised by the M4 mutation. In addition, the ability of Vpx to enhance HIV-1 infectivity required proteasome function in that Vpx failed to enhance permissiveness of macrophages to HIV-1 infection in macrophages in which proteasome function was disrupted by ALLN or proteasome inhibitor 1 (Figure 6C).

Vpx function requires damaged DNA binding protein 1 (DDB1)

Recent studies have demonstrated that the ability of HIV-1 Vpr to induce cell cycle arrest requires the E3 ubiquitin ligase complex scaffolding factor, damaged DNA binding protein 1 (DDB1) [26–30]. Therefore, we examined whether the ability of Vpx to

Figure 4. Differential impact of proteasome inhibition on SIV<sub>WT</sub> and HIV-1 infection of macrophages. Effects of 3 different proteasome inhibitors on SIV infection of macrophages and COS cells and HIV-1 infection of macrophages are indicated. Viral infection (2-LTR cDNA) was gauged at 24 and 48 h post infection (error bars and s.d. of 3 replicate measures of a single DNA sample). doi:10.1371/journal.ppat.1000057.g004
counteract the macrophage restriction to SIV and HIV-1 infection was DDB1-dependent. In 293T cells, endogenous DDB1 associated with a wild-type SIV Vpx protein but not with a SIV Vpx mutant lacking lysine residues (VpxM4) (Figure 7A). A specific association of SIV Vpx with DDB1 was apparent in coimmuno-precipitation experiment with either FLAG-tagged Vpx or with HA-tagged Vpx proteins (Figure 7A). If DDB1 is a functional Vpx interactor, we would predict that DDB1 silencing would only impact SIV infection of macrophages in which the restriction was expressed but not in COS cells which lack the restriction. In addition, HIV-1 Vpr did not antagonize a macrophage restriction. The activity of the restriction in HIV-1 was only revealed by the ability of Vpx to enhance HIV-1 infection of macrophages. Therefore, a prediction is that DDB1 silencing should not inhibit infection of macrophages by HIV-1. DDB1 specific siRNAs efficiently reduced DDB1 expression in COS cells and in macrophages (Figure 7B, left panels). While DDB1 silencing had no significant effect on SIV infection of COS cells (p>0.05), SIV infection was significantly impaired (p<0.005) in DDB1-depleted macrophages (Figure 7C, upper right panel). In contrast, macrophage infection by HIV-1 was not affected by DDB1 silencing (Figure 7C, lower right panel). We also used an independent strategy to deplete DDB1 in macrophages to assess its role in virus infection. Similar to the results obtained with siRNA mediated DDB1 depletion, depletion of DDB1 using DDB1-specific shRNAs also specifically impaired the susceptibility of primary macrophages to SIV infection but not HIV-1 infection (Figure S3). Therefore, DDB1 appears to be a specific Vpx cofactor in primary macrophages.

We next examined whether DDB1 was required for the ability of Vpx to counteract the restriction to HIV-1 infection. Since Vpx, when packaged in HIV-1 virions, enhanced macrophage infection,
we examined whether Vpx enhanced HIV-1 infection in DDB1 depleted macrophages. While packaging of Vpx in HIV-1 particles markedly increased infectivity for macrophages transfected with a scrambled siRNA (Figure 8A) silencing of DDB1 in macrophages significantly reduced (p < 0.002) the ability of Vpx to enhance HIV-1 infection (Figure 8A). However, DDB1 silencing had no significant effect (p > 0.05) on the infectivity of HIV-1 which had not packaged Vpx (Figure 8A). Since SIV Vpr but not SIV Vpx was essential for macrophage infection (Figure 1A), we examined whether fusion of DDB1 to SIV Vpr was sufficient to allow SIV Vpr to counteract the macrophage restriction. Packaging of Vpr alone into a Vpr and Vpx deleted SIV (SIVΔAXR) did not permit macrophage infection. In contrast, there was a partial and significant (p < 0.005) restoration of infectivity when a Vpr-DDB1 fusion was packaged relative to infectivity of virions in which the DDB1 protein was not packaged (Figure 8C). Although ubiquitylation was necessary for the ability of Vpx to counteract the restriction to HIV-1 and SIV infection of macrophages, DDB1 protein was not required for Vpx ubiquitylation (Figure 8C). Mono and poly ubiquitylated forms of Vpx were evident and apparently increased in cells in which DDB1 expression was reduced by RNA interference (Figure 8C). Collectively, these results suggest that DDB1 is required for the ability of Vpx to antagonize a restriction to infect macrophages by HIV-1 and SIV but that DDB1 is not required for Vpx ubiquitylation.

**Discussion**

Our study suggests that the function of Vpx is to antagonize an antiviral restriction in macrophages. Vpx exhibits similarities with the Vif protein of primate lentiviruses in that inactivation of the restriction required the proteasome/ubiquitin system. A role for the proteasome/ubiquitin system is provided by our demonstration that ubiquitylation mutants of Vpx are functionally attenuated and treatment of macrophages with proteasome disrupting agents specifically reduces their susceptibility to SIV infection but not HIV-1 infection. The inhibitory effect of proteasome inhibitors on SIV infection of primary macrophages as reported in our study appears to be at odds with studies demonstrating that HIV-1...
Figure 7. Inactivation of the macrophage restriction to SIV by Vpx requires DDB1. (A) Association of SIV Vpx with endogenous DDB1. Association of DDB1 with wild-type Vpx (VpxWT) and non-ubiquitylated Vpx (VpxM4) was evaluated in 293T cells expressing FLAG-tagged Vpx (left panels) or HA-tagged Vpx (right panels) or IRES-GFP as a control. FLAG and HA immunoprecipitates were immunoblotted with DDB1 or FLAG and HA antibodies (upper panels). Levels of endogenous DDB1 and expressed Vpx in cell lysates were confirmed by Western blotting with a DDB1 antibody and with FLAG/HA antibodies respectively (lower panels). (B) Efficiency of siRNA-mediated silencing of DDB1 expression in COS cells and in macrophages was evaluated by Western blotting with DDB1 antibody at the indicated intervals post siRNA-transfection (Scr - scrambled siRNA control). (C) Impact of DDB1 silencing on SIV and HIV-1 infection of COS cells and macrophages. SIV and HIV-1 infection was gauged from the quantity of viral cDNA (2-LTR) at 24, 48 and 72 h post infection (+, p > 0.05; *, p < 0.005) (error bars are s.d. of replicate PCRs of a single DNA sample). doi:10.1371/journal.ppat.1000057.g007

Figure 8. DDB1 is required for the ability of Vpx to counteract the restriction to macrophage infection by HIV-1. (A) SIV Vpx (or GFP as a control) was packaged into HIV-1ΔVpr virions as described in Figure 5. Infectivity of those viruses for DDB1-depleted macrophages (DDB1 siRNA) or control macrophages (Scr siRNA) were evaluated from levels of viral cDNA 24 h later (+, p > 0.2; *, p < 0.002). (B) DDB1 packaging partially substitutes for Vpx. A Vpx/Vpr deletion mutant of SIV (SIVΔXR) was co-transfected with vectors expressing SIV Vpr, SIV Vpx, DDB1 or a Vpr-DDB1 fusion. Infectivity of the resulting viruses for macrophages was evaluated from levels of SIV cDNA at 24 and 48 h post infection (*, p < 0.005). (C) Impact of DDB1 silencing on Vpx ubiquitylation. 293T cells were cotransfected with DDB1 or scrambled siRNAs and with HIS-ubiquitin and HA-Vpx or IRES-GFP expression plasmids as outlined in Figure 3. Ubiquitin-conjugated proteins were nickel purified and immunoblotted for Vpx (HA). Cell lysates were directly blotted for Vpx and DDB1 proteins (lower two panels). doi:10.1371/journal.ppat.1000057.g008
infection of cell lines is enhanced in the presence of proteasome inhibitors [31–35]. The majority of these studies have involved cell lines and one of these studies [31] has suggested that proteasome inhibitors enhance HIV-1 infection by inducing G2/M cell cycle arrest thereby imparting a cellular environment that is more permissive to infection. Our study used primary macrophages and since these cells are terminally differentiated and nondividing, enhancing effects of proteasome inhibitors due to cell cycle arrest would not be manifest. A comparison of our study with the study of Goujon et al. [17] demonstrates that Vpx is essential for infection of macrophage (our study) and of dendritic cells [17]. However, there are some differences in the results obtained with Vpx mutant viruses in these two systems. In the study of Goujon et al. [17], the proteasome inhibitor MG132 marginally (1–2 fold) increased viral DNA accumulation in dendritic cells in the presence of Vpx whereas in our study, proteasome inhibitors markedly inhibited infection of macrophages by SIV but not HIV-1. Since Goujon et al. [17] reported that primary human dendritic cells were highly sensitive to the toxic effects of MG132, it is possible that differences in treatment conditions that can be employed in macrophages versus dendritic cells could account for these differences. The study of Goujon et al. [17] also showed an enhancement of SIV infection in the absence of Vpx. We did not examine the effects of proteasome inhibitors on a Vpx-deleted virus in macrophages because this variant was essentially dead in these cells.

Our study implicates DDB1 as a cellular cofactor of Vpx which is necessary for the ability of Vpx to counteract the macrophage restriction. This is supported by several independent experiments. DDB1 silencing in macrophages specifically impaired their susceptibility to infection by SIV and, in addition, impaired the ability of Vpx to enhance infectivity of macrophages by HIV-1. It is not possible to conclude at present whether DDB1 association accounts, in totality, for the biological activity of Vpx. DDB1 silencing led to a 5–10 fold reduction in SIV infectivity of macrophages whereas there was a 100 fold infectivity defect imparted by deletion of Vpx. However, RNA silencing failed to completely deplete DDB1 from primary macrophages and it is possible that residual DDB1 allowed some retention of Vpx activity in these macrophages. We also present evidence that DDB1 binds to ubiquitylated Vpx and that lysine mutants of Vpx which are inefficiently ubiquitylated exhibit reduced DDB1 binding and are impaired in their ability to support SIV infection of macrophages. Using a Vpx mutant lacking lysine residues, we present evidence that Vpx ubiquitylation is important for association with DDB1 and to counteract the macrophage restriction. Although we attribute loss of Vpx function to lack of ubiquitylation and loss of DDB1 binding, we cannot rule out the possibility that loss of function of the mutant protein was due to indirect effects of the mutations on protein structure. However, at the very least, the Vpx lysine mutant is packaged within virions which suggests that it is competent for interaction with the p6 domain of the Gag polyprotein. As with DDB1 silencing, the reduction in Vpx function imparted by mutation of all four lysines in Vpx caused a no more than a 10 fold defect in Vpx function (for example, see Figure 3B; Figure 6A,B). Therefore, ubiquitylation and DDB1 association may not fully account for the biological activity of Vpx in macrophages. However, polyubiquitylated forms of Vpx were still evident in cells transfected with a Vpx mutant lacking all lysine residues (Figure 3A). This suggests some degree of Vpx ubiquitynation on nonlysine residues [24,25]. Identification and mutagenesis of all ubiquitination residues on Vpx will be required before the degree to which Vpx activity depends upon ubiquitynation can fully be assessed. Our study also suggests that DDB1 is not required for Vpx ubiquitynation but that Vpx ubiquitynation is necessary for association with DDB1. Therefore, the loss of function observed with the Vpx lysine mutant is likely to reflect a loss in DDB1 binding. Although SIV Vpr did not counteract the macrophage restriction, fusing it to DDB1 partially conferred this ability. This suggests that the function of Vpx may be to tether DDB1 to the reverse transcription complex upon which the restriction acts. Our study also indicates that DDB1 is required for the ability of Vpx to counter the macrophage restriction to HIV-1 infection. HIV-1 Vpr did not exhibit the ability to counter the macrophage restriction. For this reason, silencing of DDB1 did not impair susceptibility of macrophages to HIV-1 infection. However, the fact that the restriction was active against HIV-1 was revealed by the demonstration that Vpx greatly increased the permissivity of macrophages to HIV-1 infection. In this situation, silencing of DDB1 inhibited the ability of Vpx to enhance macrophage infection by HIV-1. Although Vpx is a virion protein, we do not know if DDB1 itself is packaged within virions. However, since silencing of DDB1 in the target cell inhibited SIV infection, this suggests that Vpx usurps DDB1 after infection of the target cell and likely, within the context of the reverse transcription complex.

Our study also reveals a paradox with regards to the functional consequences of HIV-1 Vpr and HIV-2/SIV Vpx interaction with DDB1. DDB1 mediates the cell cycle arrest property of HIV-1 Vpr. DDB1 was also necessary for the ability of SIV Vpx to counteract the macrophage restriction. However, SIV Vpx, although able to interact with DDB1, does not induce cell cycle arrest. Furthermore, the ability of HIV-1 Vpr to interact with DDB1 does not appear sufficient to confer upon HIV-1 Vpr the ability to efficiently counteract the macrophage restriction. Therefore, there are likely to be different biological outcomes that are dictated by the nature of the interactions that HIV-1 Vpr and SIV Vpx forge with DDB1 and its associated E3 ubiquitin ligase complex components. Further insight into the mechanisms employed by HIV-1 Vpr and HIV-2/SIV Vpx to enhance macrophage infection may be revealed once the macrophage restriction itself is identified.

Materials and Methods

Provirial DNAs, virus stocks and infections

The infectious molecular clone SIVSM PBj1.9 was used for the majority of experiments in this study. This clone, which is representative of the HIV-2/SIVSM group of viruses, was derived from short-term peripheral blood mononuclear cell (PBMC) cultures. Unlike many other HIV-2 and SIVSM clones, PBj1.9 has a complete set of uninterrupted accessory genes and replicates efficiently in macrophages and represents a physiologically relevant virus strain. Mutations which abrogated the translation of Vpx and Vpr genes are as described previously [4]. HIV-GFP (a gift of Paul Clapham, University of Massachusetts Medical School) contains an EGFP gene inserted between the envelope stop codon and nef within the HIV-1NL4-3 backbone. GFP expressing variants of wild type and ∆Vpx SIV contain an EGFP gene inserted between Bst 1107I sites within the viral envelope gene (as schematized on Figure 2). Wild type and ∆Vpx HIV-1 variants were studied in the context of HIV-1NL4-3. For the generation of viral stocks, 293T cells were transfected with proviral DNAs (25 µg) using a modified calcium phosphate/DNA precipitation method (Stratagene). Viruses were pseudotyped with VSV envelope glycoproteins by cotransfection of proviral DNAs with a plasmid expressing the VSV envelope glycoprotein. For encapsidation of wild type and mutant Vpx and Vpr proteins,
293T cells were co-transfected with proviral DNAs and plasmids expressing Vpx and Vpr proteins. The DNA ratio for pVSV-G, proviral clones and pIRE2-EGFP-Vpx was 1:14:1. For encapsidation of Vpr-DDB1 fusion proteins, 293T cells were co-transfected with an SIV deltaVpx/deltaVpr proviral clone, pIRE2-EGFP Vpr-dDDB1 and pVSV-G. The DNA ratio for pVSV-G, proviral clone and DDB1 expression plasmids was 1:14:1. HIV-1 and SIV stocks were normalized on the basis of reverse transcriptase activity. Viral infection efficiency was gauged from synthesis of viral cDNA products at early intervals (24 and 48 h) post-infection. PCR conditions for amplification of SIVsm and HIV-1 2-LTR cDNAs are as described previously [4,36]. cDNA copy numbers were expressed on a per cell basis after quantitation of genomic DNA copy numbers using PCR and primers to the CCR5 gene [36]. Macrophages were initially infected with VSV-pseudotyped SIV variants harboring intact or defective Vpx genes. Viruses used in the initial infection additionally lacked an intact envelope open reading frame. Macrophages were then super-infected with SIV variants which harbored intact envelope genes. As a consequence, cDNA products generated specifically by the super-infecting virus could be identified. SIV cDNA products were amplified in two rounds of PCR with JumpStart™ Red Hot Taq™ DNA polymerase (Sigma). First round products were amplified using forward (taacaggaacaccagcaccaaca) and reverse (catctgctttccctgacaa) primers. Second-round products were amplified using forward (taacaggaacaccagcaccaaca) and reverse (aagctaaatgctgggtgcga) primers.

**Gradient purification of virions**

Supernatants from 293T cells transfected with infectious molecular clones were cleared of cellular debris by low-speed centrifugation (1500 g, 10 min) and then filtered (0.45 µm). Virions in clarified supernatants were harvested (10,000 g, 2 h) and resuspended in serum-free medium (500 µl). Concentrated virions were applied to a 15–60% w/v continuous sucrose gradient and virions were resolved at 200,000 x g for 16 h. Gradient fractions (0.5 ml) were collected and virus levels in each fraction were measured by reverse transcriptase activity. Virus particles in individual gradients were pelleted and resuspended in sample buffer and the presence of encapsidated Vpx proteins was examined by Western blotting with an zHA antibody.

**Macrophages and cell lines**

Peripheral blood monocytes were obtained by elutriation and counter current centrifugation and maintained 2 days in DMEM containing 10% human serum and monocyte colony stimulating factor (MCSF) (RD Systems) and for a further 5 days in medium lacking MCSF prior to use in experiment. 293T, Hela and COS cells were maintained in DMEM containing 10% FBS.

**Proteasome inhibition**

Macrophages or COS cells (8x10^6) in 24 well plates were directly infected with VSV-G-pseudotyped viruses (1x10^6 cpm RT/ml or 1 ug p24/ml) in the presence of proteasome inhibitors including Lactacycline (10 µM), ALLN (50 µM) and Proteasome inhibitor 1 (50 µM). After 3–5 h, supernatant was removed and replaced with fresh medium containing proteasome inhibitors. After 24 and 48 h post-infection total DNA was isolated using DNAzol reagent (Invitrogen) and analyzed by real-time PCR assay for 2LTR circles.

**Cell staining**

For FACs analysis, COS cells and human macrophages were stained with 3.5 µM CellTracker Green CMFDA (3-chloromethylfluorescein diacetate) and 24 µM CellTracker Blue CMAC (7-amino-4-chloromethylcoumarin), respectively. For fluorescence microscopy, COS cells and macrophages were stained with 2.5 µM DiO (3,3’-diododecyloxacarbo cyanine perchlorate) and 12 µM Dil (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate) respectively, according to manufacturer’s instructions (Molecular Probes).

**Cell fusion**

Generation of macrophage homokaryons was achieved by polyethylene glycol (PEG). Briefly, labeled cells, 15x10^6 each group, were mixed and centrifuged at 250 g. 50% PEG-1450 was added dropwise to the pellet and cells incubated for 2 min at 37°C with gentle mixing. 1 ml PBS was then added dropwise to the cells over 1 min, followed by 3 ml of 2% FBS/PBS over another 2 minutes. Cells were washed 3 times with 2% FBS/PBS and plated in a 100 mm culture dish (1x10^7 cells/dish). COS-macrophage and COS-COS cell fusion was achieved using paramyxovirus hemagglutinin-neuraminidase (HN) protein and fusion (F) protein. Briefly, COS cells were transfected with pCAGGS-HN and pCAGGS-F expression vectors encoding HN and F proteins of Newcastle disease virus (gift of Prof. T. Morrison) [37]. Sixteen to twenty hours post-transfection, COS cells were stained, mixed with stained macrophages (ratio 1:1.5) and plated in 100 mm dishes. COS homokaryons were generated at 1:1 ratio. After overnight incubation, cells were infected with either SIV<sub>VT</sub> or SIV<sub>DDB1</sub> for 24 h. Cell sorting was performed with a FACSARia flow cytometer using the FACS DIVA software (Becton Dickinson). Double-stained cells were sorted. Total DNA was isolated using DNeasy Blood and Tissue Kit (Qiagen) and analyzed by real-time PCR assay for 2LTR circles.

**Plasmids**

The SIVsm Vpx and HIV-1 Vpr genes were amplified from PBj1,9 and NL4.3 proviral clones respectively, and inserted into a pIRE2-EGFP vector (BD) either with or without a N-terminal minimum HA epitope. The upstream primer for each PCR product provided a Kozak sequence. The Vpx lysine mutants (K68,77,84,85R) were generated by Quikchange XL site-directed mutagenesis (Stratagene). The DDB1 gene was amplified and subcloned from PBj-hp125 (ATCC, MBA-126) and inserted into pIRE2-EGFP as an in frame fusion with the C-terminal of SIV Vpr. A Flag epitope was added to the N-terminal of DDB1 as flaming sequences between Vpx and DDB1. As a control, a N-terminal Flag tagged DDB1 was inserted into pIRE2-EGFP.

**Analysis of Vpx ubiquitylation**

293T cells were co-transfected with HA-Vpx, HA-Vpx lysine mutants or a pIRE2-EGFP empty vector and pRGB4-6His-myc-Ubiquitin at a 1:4 ratio using lipofectamine 2000 (Invitrogen). Non-6His tagged Ubiquitin was included as a control for Ni-NTA pull down. 36 h after transfection, the 6His-ubiquitin conjugated proteins were purified using Ni-NTA Magnetic Agarose beads (Qiagen) under native conditions [38]. Briefly, cells were lysed in detergent buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100 and protease inhibitor cocktail) and clarified by centrifugation at 14,000 rpm for 15 min. The cell lysates were incubated with Ni-NTA beads overnight at 4°C in detergent buffer with 300 mM NaCl, 20 mM imidazole and 5 µM MG132. The beads were washed in lysis buffer and attached proteins were eluted in elution buffer (50 mM Na2HPO4, 375 mM NaCl, 1% Triton, 250 mM imidazole-pH 8.0).
Immunoblotting

Virus pellets were lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% NaDeo, 0.1% SDS and protease inhibitor cocktail) lysates of transfected cells or gradient purified virions were boiled in sample buffer, resolved by SDS/PAGE and Western blotted with the following antibodies: HA-Vpx (HA, 1B6, Covance), myc-Ubiquitin (α-ubiquitin, P4G7, Covance; α-Myc 9E10, Sigma), Caspid (polyclonal, ABL), γ-tubulin (GTU-88, Sigma), Flag-Vpx (M2, F3165, Sigma), DDB1 (Goat polyclonal antibody PC718, Calbiochem).

RNA interference of DDB1

The siRNA sequences for DDB1 silencing in macrophages, COS-1 or 293T cells were

siRNA1: GCAAGGACCTGCTGTATTA
siRNA2: GCAATGCCAGCATTGACTTA
siRNA3: CCTGCATCTGGAGATTTAA

The Scrambled control siRNA sequence was CAGTCGCGTTTGCGACTGG

Supporting Information

Figure S1 Susceptibility of macrophages to infection by wild type and Vpx-deleted SIVmac variants. Virus infection was gauged from the levels of late cDNA and 2-LTR cDNA products of reverse transcription at 24 and 48 h post infection. Found at: doi:10.1371/journal.ppat.1000057.s001 (0.09 MB TIF)

Figure S2 Differential impact of proteasome inhibition on HIV-2Vpx infection of macrophage and COS cells. Effects of three different proteasome inhibitors on HIV-2 infection are indicated. Viral infection (2-LTR cDNA) was gauged 24 and 48 h post infection (error bars are s.d. of 3 replicate measures of a single sample). Found at: doi:10.1371/journal.ppat.1000057.s002 (0.12 MB TIF)

Acknowledgments

We thank A. Dauphin for research support and S. Swincer for statistical analysis and advice, B. Mellor for preparation of the figures, K. Deartie for manuscript presentation, and T. Morrison for Newcastle disease virus HN and F expression plasmids and J. Skowronski for DDB1 shRNA vectors. We also wish to acknowledge the University of Massachusetts Center for AIDS Research (CFAR) and the AIDS Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health (NIH) for assay support and reagents.

Author Contributions

Conceived and designed the experiments: N. Sharova, Y. Wu, X. Zhu, R. Stranska, R. Kaushik, M. Sharkey, M. Stevenson. Performed the experiments: N. Sharova, Y. Wu, X. Zhu, R. Stranska, M. Sharkey. Analyzed the data: N. Sharova, Y. Wu, X. Zhu, R. Stranska, M. Stevenson. Wrote the paper: N. Sharova, Y. Wu, X. Zhu, R. Stranska, M. Stevenson.

References

1. Emerman M, Malim MH (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280: 1890–4.
2. Sheehy AM, Gaddis NC, Cho JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646–50.
3. Neil SJ, Zang T, Bieniarz PD (2000) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 24: 406–13.
4. Fletcher TM 3rd, Bricahce B, Sharova N, Newman MA, Sivathanu G, Sharp PM, Emerman M, Hahn BH, Stevenson M (1996) Nuclear import and cell cycle arrest functions of the HIV-1 Vpr gene product are encoded by two separate genes in HIV-2/SIMmac. EMBO J 15: 6155–63.
5. Lu Y-L, Spermann P, Ratner L (1993) Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 67: 6542–50.
6. Cohen EA, Dehnai G, Sodroski JG, Haseltine WA (1990) Human immunodeficiency virus type 1 vpr product is a virion-associated regulatory protein. J Virol 64: 3097–9.
7. Kappes JC, Morrow CD, Lee SW, Jameson BA, Kent SBH, Hood LE, Shaw GM, Hahn BH (1988) Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac. J Virol 62: 3501–9.
8. He J, Choe S, Walker R, DeMaria P, Rong R, Ragsdale NR, Odero M, Landau NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting the p34cdc2 activity. J Virol 69: 6705–11.
9. Jowett JB, Pannell V, Poon B, Shah NP, Chen M-L, Chen B (1995) The human immunodeficiency virus type 1 vpr gene product arrests infected T cells in the G2 phase of the cell cycle. J Virol 69: 6304–13.
10. Re F, Braaten D, Franke EK, Lahan J (1995) Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2 cyclin B. Journal of Virology 69: 6509–64.
11. Roed ME, Wu LI, Emerman M (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69: 882–8.
12. Bouchard M, Benichou S, Roy F, Navarro JM, Agostiini I, Spire B, Camonis J, Slupphaug G, Vigne R, Benarous R, Sire J (1996) Human immunodeficiency virus type 1 Vpr binds to the uracil DNA glycosylase DNA repair enzyme. J Virol 70: 697–704.

13. Balliet JW, Kolson DL, Eager G, Kim FM, McGann KA, Srinivasan A, Collman R (1994) Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 200: 625–31.

14. Conner RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mono-nuclear phagocytes. Virology 206: 935–44.

15. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mono-nuclear phagocytes. Virology 206: 935–44.

16. Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mono-nuclear phagocytes. Virology 206: 935–44.

17. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Sleigh R, Sharkey M, Newman MA, Hahn B, Stevenson M (1998) Differential association of uracil DNA glycosylase with SIV SM Vpr and Vpx proteins. Retrovirology 5: 338–43.

18. Hrecka K, Gierszewska M, Srivastava S, Kosacz-Kwiesiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J (2007) Lentiviral Vpr usurps Cathepsin D and the Ubiquitin-26S Proteasome System in Macrophages. PLoS Pathog 4: e85. doi:10.1371/journal.ppat.0030085.

19. Dewhurst S, Embretson JE, Anderson DC, Mullins JI, Fultz PN (1990) Sequence analysis and acute pathogenicity of molecularly cloned SIV. Nature 345: 363–40.

20. Simon JHM, Gaddio NC, Fourrier RAM, Malim MH (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Med 4: 1397–400.

21. Madani N, Kabat D (1998) An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. Journal of Virology 72: 10251–5.

22. Cullen BR (2006) Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80: 1067–76.

23. Harris RS, Liddament MT (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4: 388–77.

24. Wang X, Herr RA, Clua WJ, Lybarger L, Wiertz EJ, Hansen TH (2007) Ubiquitination of serine, threonine or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J Cell Biol 177: 613–24.

25. Cardwell K, Coscoy L (2005) Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309: 127–30.

26. Le Rouzie E, Beladouni N, Estrabaud E, Morel M, Rain JC, Tranzy C, Margottin-Gogaert F (2007) HIV-1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cadherin-Dependent Ubiquitin Ligase. J Immunol 179: 6977–84.

27. DeHart JL, Zimmerman ES, Ardon O, Monteiro-Filho CM, Aeganaraz ER, Planelles V (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4: 37.

28. Schwartz O, Marzchel V, Friguet B, Arenzana-Seisdedos F, Heard JM (1998) Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72: 3894–903.

29. Tan L, Ehrlich E, Yu XF (2005) DDB1 and Cad4A Are Required for Human Immunodeficiency Virus Type-1 Vpr-Induced G2 Arrest. J Virol 81: 10822–30.

30. Belzile JP, Duijts G, Rougeau N, Mercier J, Finzi A, Cohen EA (2007) HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4A(VPRBP) E3 Ubiquitin Ligase. PLoS Pathog 3: e65. doi:10.1371/journal.ppat.0030085.

31. Groschel R, Bushman F (2005) Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus. J Virol 79: 5695–704.

32. Schwartz O, Marzchel V, Friguet B, Arenzana-Seisdedos F, Heard JM (1998) Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72: 3894–903.

33. Wei BL, Denton PW, O’Neill E, Lao T, Foster JL, Garcia JV (2005) Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J Virol 79: 5705–12.

34. Santoni de Sio FR, Casco P, Zangale A, Gasparini M, Naldini L (2006) Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107: 4257–65.

35. Wu X, Anderson JL, Bryant EM, Joseph AM, Hope TJ (2006) Proteasome inhibitors uncouple rhesus TRIMalpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A 103: 7465–70.

36. Sharkey ME, Teo I, Greenough T, Shavali N, Lai KK, Sullivan JL, Bucy RP, Kositriska LG, Haase A, Verryard C, Davaro RR, Cheeseman SH, Dalry JP, Rovit AS, Shaz B, Lai AS, Boey G, Nelson M, Gazzard B, Shaunik S, Stevenson M (2000) Persistence of epigenomic HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nature Med 6: 76–81.

37. McGinness LW, Morrison TG (2006) Inhibition of receptor binding stabilizes Newcastle disease virus HA and F protein-containing complexes. J Virol 80: 2894–900.

38. Ward CL, Omura S, Kopito RR (1995) Degradation of GPRF by the ubiquitin-proteasome pathway. Cell 83: 121–7.

39. Janas J, Skowronski J, Van Aelst L (2006) Lentiviral delivery of RNAi in T cells. J Exp Med 194: 1407–19.

40. Schwartz O, Marzchel V, Friguet B, Arenzana-Seisdedos F, Heard JM (1998) Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72: 3894–903.

41. Schwartz O, Marzchel V, Friguet B, Arenzana-Seisdedos F, Heard JM (1998) Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72: 3894–903.

42. Schwartz O, Marzchel V, Friguet B, Arenzana-Seisdedos F, Heard JM (1998) Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 72: 3894–903.